Saxony Capital Management LLC Invests $203,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Saxony Capital Management LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, Holdings Channel.com reports. The fund purchased 2,426 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

A number of other large investors have also modified their holdings of GILD. Sunbelt Securities Inc. grew its stake in shares of Gilead Sciences by 26.4% during the first quarter. Sunbelt Securities Inc. now owns 11,603 shares of the biopharmaceutical company’s stock worth $850,000 after acquiring an additional 2,426 shares during the last quarter. Brookstone Capital Management boosted its position in Gilead Sciences by 751.1% in the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock valued at $9,322,000 after buying an additional 112,305 shares during the last quarter. Future Financial Wealth Managment LLC purchased a new stake in Gilead Sciences in the first quarter valued at approximately $161,000. Matrix Asset Advisors Inc. NY boosted its position in Gilead Sciences by 4.8% in the first quarter. Matrix Asset Advisors Inc. NY now owns 311,545 shares of the biopharmaceutical company’s stock valued at $22,821,000 after buying an additional 14,200 shares during the last quarter. Finally, DGS Capital Management LLC boosted its position in Gilead Sciences by 13.1% in the first quarter. DGS Capital Management LLC now owns 8,809 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 1,021 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. BMO Capital Markets upped their target price on Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $78.00 to $100.00 in a report on Monday, October 7th. Royal Bank of Canada boosted their price target on Gilead Sciences from $74.00 to $75.00 and gave the company a “sector perform” rating in a report on Friday, October 4th. Piper Sandler reissued an “overweight” rating and issued a $95.00 price target on shares of Gilead Sciences in a report on Wednesday, September 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Ten equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Price Performance

NASDAQ GILD opened at $88.16 on Wednesday. The stock has a 50-day simple moving average of $81.61 and a 200 day simple moving average of $73.07. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock has a market capitalization of $109.83 billion, a PE ratio of 244.89, a P/E/G ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $88.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Research analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.49%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s dividend payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.